Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
| 62.56 | |
| 62.04 | |
| - | |
| 65.48 | |
| 62.04 | |
| 8.624-91.5 | |
| 7 051 M | |
| 111 M | |
| 0 | |
| 1.024 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Viking Therapeutics VKTX reported second-quarter 2024 loss per share of 20 cents, narrower than the Zacks Consensus Estimate of a loss of 26 cents. The company had incurred a loss of 19 cents per shar...
Nvidia, Ford, Chipotle, Viking Therapeutics, Tesla: Why These 5 Stocks Are On Investors' Radars Today On Wednesday, major U.S. indices closed significantly lower. The Dow Jones Industrial Average fel...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
